Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSTP1 | P09211 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | BCHE | P06276 | 4/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | METAP2 | P50579 | 2/20 | 0.33 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MMP9 | P14780 | 1/20 | 0.32 |
| ▸ | MMP12 | P39900 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | GSTA2 | P09210 | 1/20 | 0.31 |
| ▸ | GSTM1 | P09488 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12306528 | 0.85 | ALDH1A1 (0.37) | GSTP1ALDH1A1BCHECYP2D6MAPK1 | |
| SCHEMBL5696092 | 0.84 | ALDH1A1 (0.39) | GSTP1ALDH1A1BCHECYP2D6MAPK1 | |
| SCHEMBL14511230 | 0.84 | ALDH1A1 (0.39) | GSTP1ALDH1A1BCHECYP2D6MAPK1 | |
| SCHEMBL5696091 | 0.84 | ALDH1A1 (0.39) | GSTP1ALDH1A1BCHECYP2D6MAPK1 | |
| SCHEMBL13722194 | 0.83 | — | — | |
| SCHEMBL2718131 | 0.83 | TDP1 (0.38) | GSTP1 | |
| SCHEMBL5846888 | 0.80 | ALDH1A1 (0.36) | GSTP1ALDH1A1BCHECYP2D6MAPK1 | |
| SCHEMBL1098026 | 0.80 | ALDH1A1 (0.36) | GSTP1ALDH1A1BCHECYP2D6MAPK1 | |
| SCHEMBL1098024 | 0.80 | ALDH1A1 (0.36) | GSTP1ALDH1A1BCHECYP2D6MAPK1 | |
| SCHEMBL14511226 | 0.80 | ALDH1A1 (0.36) | GSTP1ALDH1A1BCHECYP2D6MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088746-B2 | Bis-modified bicyclic nucleic acid analogs | ISIS PHARMACEUTICALS, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-8030467-B2 | 5′-modified bicyclic nucleic acid analogs | ISIS PHARMACEUTICALS, INC. (US) | 2011-10-04 | — | — | US | disclosed |
| US-20100184966-A1 | 5'-MODIFIED BICYCLIC NUCLEIC ACID ANALOGS | ISIS PHARMACEUTICALS, INC. (US) | 2010-07-22 | — | — | US | disclosed |
| US-7750131-B2 | 5′-modified bicyclic nucleic acid analogs | ISIS PHARMACEUTICALS, INC. (US) | 2010-07-06 | — | — | US | disclosed |
| US-20100121045-A1 | BIS-MODIFIED BICYCLIC NUCLEIC ACID ANALOGS | IONIS PHARMACEUTICALS, INC. | 2010-05-13 | — | — | US | disclosed |
| US-7666854-B2 | Bis-modified bicyclic nucleic acid analogs | ISIS PHARMACEUTICALS, INC. (US) | 2010-02-23 | — | — | US | disclosed |
| US-20090192302-A1 | 5'-MODIFIED BICYCLIC NUCLEIC ACID ANALOGS | ISIS PHARMACEUTICALS, INC. (US) | 2009-07-30 | — | — | US | disclosed |
| US-20090156792-A1 | BIS-MODIFIED BICYCLIC NUCLEIC ACID ANALOGS | IONIS PHARMACEUTICALS, INC. | 2009-06-18 | — | — | US | disclosed |
| US-7547684-B2 | 5′-modified bicyclic nucleic acid analogs | ISIS PHARMACEUTICALS, INC. (US) | 2009-06-16 | — | — | US | disclosed |
| US-20070287831-A1 | 5'-MODIFIED BICYCLIC NUCLEIC ACID ANALOGS | ISIS PHARMACEUTICALS, INC | 2007-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100121045-A1 | BIS-MODIFIED BICYCLIC NUCLEIC ACID ANALOGS | NSUN2, ADAR, POLRMT | GSTP1 3277/4885ALDH1A1 3035/4885BCHE 1026/4885 |
| US-20090156792-A1 | BIS-MODIFIED BICYCLIC NUCLEIC ACID ANALOGS | NSUN2, ADAR, POLRMT | GSTP1 3277/4885ALDH1A1 3035/4885BCHE 1026/4885 |
| US-20100184966-A1 | 5'-MODIFIED BICYCLIC NUCLEIC ACID ANALOGS | NT5C3B, NSUN2, ADAR | GSTP1 4049/4885ALDH1A1 3273/4885BCHE 2468/4885 |
| US-20090192302-A1 | 5'-MODIFIED BICYCLIC NUCLEIC ACID ANALOGS | NT5C3B, NSUN2, ADAR | GSTP1 4049/4885ALDH1A1 3273/4885BCHE 2468/4885 |
| US-20070287831-A1 | 5'-MODIFIED BICYCLIC NUCLEIC ACID ANALOGS | NT5C3B, NSUN2, ADAR | GSTP1 4049/4885ALDH1A1 3273/4885BCHE 2468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.